TCT 1438: Emergent Valve-in-Valve TAVR at High Risk of Coronary Occlusion Treated With Leaflet Modification (ShortCut)

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Consultant Fee/Honoraria/Speaker’s Bureau - Boston Scientific Corporation; Shockwave Medical; Medtronic; Edwards Lifesciences</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Penumbra</li></ul>